By Dr. Charles Kamen, MD — Board-Certified Neurologist
Las Vegas is not exactly known for moderation. But for the 700,000+ residents of the Las Vegas Valley who are not tourists — people raising families, building careers, and trying to stay healthy in a desert climate — the weight loss conversation is deeply personal and often frustrating.
If you have been considering GLP-1 therapy for weight loss and you live in Las Vegas or anywhere in Nevada, this is the straightforward walkthrough I give my patients. No hype, no before-and-after photos with suspicious lighting. Just what actually happens when you pursue medical weight loss with a physician who takes it seriously.
Nevada has some of the highest obesity rates in the western United States. The combination of sedentary indoor culture (it is 115 degrees outside for three months of the year), shift-work schedules from the hospitality industry, and limited walkability in most neighborhoods creates a metabolic environment that diet and exercise alone cannot always overcome.
This is not a moral failing. This is physiology.
GLP-1 receptor agonists — medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — work by correcting the hormonal signals that regulate appetite and metabolism. They target the same pathways your body uses naturally, but amplify them enough to overcome the metabolic resistance that makes sustained weight loss so difficult.
As a neurologist, I can tell you that these medications work in the brain. The hypothalamic appetite centers, the mesolimbic reward pathways, the gut-brain axis — GLP-1 therapy modulates all of them. This is why patients describe not just eating less, but genuinely wanting less. The food noise quiets down.
Here is exactly what to expect when you come to LiveWell21 for a GLP-1 consultation.
This is not a telehealth mill where you answer five questions and get a prescription. Your first visit is comprehensive.
Medical history review. I need to know your full picture: previous weight loss attempts, current medications, family history of obesity and metabolic disease, history of eating disorders (this matters — GLP-1 therapy is not appropriate for everyone), thyroid function, sleep patterns, and stress levels.
Physical examination. We check vitals, body composition (not just weight — body fat percentage, lean mass, and visceral fat distribution matter more), and screen for conditions that might affect treatment.
Laboratory work. Before starting any GLP-1 therapy, I order baseline labs:
These labs serve two purposes: they rule out contraindications, and they give us objective baseline markers to track your progress beyond the scale.
Goal setting. I ask every patient the same question: "What does success look like for you?" The answer is never just a number. It is usually about energy, mobility, confidence, or getting off other medications. We define clear, measurable goals together.
Based on your assessment, I will recommend one of several approaches:
GLP-1 monotherapy — semaglutide or tirzepatide alone, appropriate for most patients.
Combined peptide therapy — GLP-1 medication paired with other peptide therapies that address complementary pathways like growth hormone optimization, inflammation reduction, or metabolic recovery.
Comprehensive metabolic protocol — for patients with complex metabolic profiles, this includes GLP-1 therapy, nutritional guidance, targeted supplementation, and ongoing monitoring.
I will explain why I am recommending a specific medication and dose. You will understand the mechanism before the needle touches your skin.
GLP-1 medications are not prescribed at full dose from day one. The titration — gradual dose increases — is critical for tolerability and safety.
You will begin at the lowest dose. For semaglutide, that is 0.25 mg weekly. For tirzepatide, it is 2.5 mg weekly.
What to expect: Most patients notice a modest decrease in appetite within the first week. Some notice nothing. Both are normal. Mild nausea is common but usually manageable. I advise patients to eat smaller meals, avoid greasy foods, and stay hydrated.
Weight loss at this stage: Variable. Some patients lose 3-5 pounds in the first month. Others see little change. The starting dose is about acclimation, not aggressive weight loss.
We increase the dose every 4 weeks, following a standardized titration schedule. This is when most patients start to feel the medication working more substantially.
What to expect: Appetite suppression becomes more noticeable. Portion sizes naturally decrease. The mental relationship with food starts to shift — patients describe thinking about food less, craving less, and feeling satisfied sooner.
Side effects: GI symptoms may intensify temporarily with each dose increase. This is expected and usually resolves within 1-2 weeks. If it does not, we may hold at the current dose longer before increasing.
Check-in appointments: I see patients at least monthly during titration. We review symptoms, adjust as needed, and repeat labs at the 8-12 week mark to track metabolic improvement.
By this point, most patients are at or near their target dose. Weight loss is typically steady at 1-2 pounds per week.
What to expect: The "new normal" is established. Patients report that their relationship with food has fundamentally changed. They eat less without fighting it. Energy levels improve as metabolic function normalizes. Many patients in physically demanding jobs — common in Las Vegas's hospitality and construction industries — report significant improvement in stamina and recovery.
I am going to give you real numbers, not marketing numbers.
Average weight loss at 6 months: 10-15% of starting body weight. For a 250-pound patient, that is 25-37 pounds.
Average weight loss at 12 months: 15-22% of starting body weight, depending on the medication and individual response.
What the scale does not show: Improvements in HbA1c, triglycerides, blood pressure, liver enzymes, and inflammatory markers. These metabolic improvements often precede significant visible weight loss and are, from a health perspective, more important.
What I tell every patient: The first 3 months require patience. The medication needs time to reach therapeutic levels, and your body needs time to respond. Patients who stick with the program through the titration phase almost universally see meaningful results. Patients who quit at week 6 because "it's not working fast enough" miss the window.
A few practical notes specific to our city.
Heat and hydration. GLP-1 medications can reduce your appetite for food AND water. In a desert climate where dehydration is a genuine medical risk, I emphasize hydration more aggressively than you might see in national guidelines. We aim for a minimum of 80 ounces of water daily, more if you work outdoors.
The restaurant culture. Las Vegas has extraordinary restaurants. You do not have to avoid them. GLP-1 therapy reduces how much you eat, not what you eat. Most patients find they can enjoy a dinner at a Strip restaurant — they just eat a third of what they used to and feel completely satisfied.
Shift work. Many of my patients work swing shifts or graveyard shifts in casinos, hotels, and hospitals. Irregular schedules complicate meal timing and sleep — both of which affect metabolic health. We build protocols that account for non-traditional schedules.
Medication storage. Semaglutide and tirzepatide must be refrigerated before first use. In a Las Vegas summer, do not leave your medication in a hot car. Ever. Heat degrades the peptide and reduces efficacy.
I see patients in person at our Las Vegas office, but I also provide telehealth consultations for patients anywhere in Nevada. GLP-1 prescribing via telehealth is legal and appropriate when done by a licensed physician with proper assessment.
If you are in Reno, Henderson, North Las Vegas, or rural Nevada, you can access the same quality of care through a virtual consultation. Lab work can be completed at any Quest or Labcorp location, and medication ships directly to your home.
For a deeper look at how to evaluate telehealth weight loss providers, I wrote a guide to safe telehealth GLP-1 prescribing that covers the red flags to watch for.
Let me be clear about what this treatment cannot do.
It is not a substitute for lifestyle. GLP-1 therapy works best when combined with improved nutrition, regular physical activity, and adequate sleep. The medication creates a window of opportunity — reduced appetite, improved metabolic signaling — but you have to walk through that window.
It is not permanent weight loss without ongoing treatment. Current evidence shows that most patients regain a significant portion of lost weight if they discontinue therapy without establishing sustainable lifestyle changes. I discuss long-term treatment planning with every patient, including strategies for eventual dose reduction or discontinuation.
It is not for everyone. Patients with a history of medullary thyroid carcinoma, MEN2 syndrome, or certain types of pancreatitis should not take these medications. Patients with active eating disorders need specialized care before considering GLP-1 therapy. This is why proper screening matters.
If you are in Las Vegas or Nevada and you are ready to have an honest conversation about medical weight loss, I would welcome the opportunity to evaluate whether GLP-1 therapy is appropriate for your situation.
The consultation starts with your story — not a sales pitch. We look at your metabolic health objectively, discuss realistic expectations, and build a plan that fits your life.
You can book an appointment online or call our office directly. Whether you come in person or connect via telehealth, the standard of care is the same.
Dr. Charles Kamen is a board-certified neurologist and the founder of LiveWell21, a peptide therapy and metabolic health practice serving Las Vegas and all of Nevada. He earned his MD from Albert Einstein College of Medicine, completed his internship at Yale-New Haven Hospital, and his neurology residency at Loma Linda University.